NCT03384511View on ClinicalTrials.gov

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

January 28, 2018

Study Completion Date

January 28, 2018

Conditions
MalignanciesStomach CancerNon-small Cell Lung CancerEsophageal CancerBreast CancerOvary CancerCervical Cancer
Interventions
DRUG

Apatinib

Patients will accept apatinib therapy and undergo baseline 18F-ALF-NOTA-PRGD2 PET/CT scans of the whole body after having met all eligibility criterias.

Trial Locations (1)

250117

Jinan

All Listed Sponsors
lead

Shandong Cancer Hospital and Institute

OTHER

NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | Biotech Hunter | Biotech Hunter